文献速递妇科

他汀类药物治疗与全国代表性老年上皮性卵巢癌女性人群生存相关

Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2017-06-07

基于SEER-Medicare数据库2007-2009年诊断的上皮性卵巢癌手术患者1431例,609例(42.6%)有他汀类处方。他汀使用与总体生存改善相关(HR=0.66,95%CI 0.55-0.81),获益限于亲脂性他汀和中强度他汀使用者。

要点

  • 在1431例接受手术的老年上皮性卵巢癌患者中,42.6%使用他汀类药物。
  • 他汀使用与死亡风险降低34%相关(HR=0.66,95%CI 0.55-0.81)。
  • 生存获益限于亲脂性他汀使用者和中强度他汀使用者。

核心结论

  • 这项SEER-Medicare分析显示,老年上皮性卵巢癌患者术后使用亲脂性他汀与总体生存改善相关。
  • 作者认为需要临床试验来评估他汀治疗对卵巢癌生存的影响。

研究设计与样本

  • 观察性研究,使用SEER登记处与Medicare索赔数据链接,纳入2007-2009年诊断的上皮性卵巢癌患者。
  • 共1431例接受手术切除的患者纳入分析,其中609例(42.6%)有他汀类处方。
  • 采用Cox回归模型分析他汀治疗与总体生存的关联。

主要发现

  • 他汀使用者平均总体生存为32.3个月,非使用者为28.8个月(p<0.0001)。
  • 他汀治疗与死亡风险降低34%相关,独立于年龄、种族、社区中位家庭收入、分期、铂类治疗和合并症(HR=0.66,95%CI 0.55-0.81)。
  • 浆液性组织学中他汀使用与总体生存改善相关(HR=0.69,95%CI 0.54-0.87),非浆液性组织学中也观察到改善(HR=0.63,95%CI 0.44-0.90)。
  • 按亲脂性和强度分类后,显著生存获益仅限于亲脂性他汀使用者和中强度他汀使用者。

关键数值与推荐

  • 他汀使用者中89%被处方亲脂性制剂。
  • 他汀使用与死亡风险降低34%相关(HR=0.66,95%CI 0.55-0.81)。
  • 浆液性组织学他汀使用HR=0.69(95%CI 0.54-0.87),非浆液性组织学HR=0.63(95%CI 0.44-0.90)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Observational studies suggest that statin therapy for cardio-protection is associated with improved survival in cancer patients. We sought to evaluate the impact of statin treatment on ovarian cancer survival in a nationally representative elderly population. METHODS: The linked Surveillance, Epidemiology, and End Results (SEER) registries and Medicare claims data on patients diagnosed with epithelial ovarian cancer in 2007-2009 were used to extract data on statin prescription fills, population characteristics, primary treatment, comorbidity and survival. Cox regression models were used to examine the association between statin treatment and overall survival. RESULTS: Among the 1431 ovarian cancer patients who underwent surgical resection, 609 (42.6%) filled prescriptions for statin. The majority of statin-users (89%) were prescribed a lipophilic formulation. Mean overall survival among statin-users was 32.3months compared to 28.8months for non-users (p<0.0001). A 34% reduction in death was associated with statin therapy, independent of age, race, neighborhood median household income, stage, platinum therapy and comorbid conditions (HR=0.66, 95% CI 0.55-0.81). Improved overall survival with statin use was observed for both serous (HR=0.69, 95% CI 0.54-0.87) and non-serous (HR=0.63, 95% CI 0.44-0.90) histologies. When statin treatment was categorized by lipophilicity and intensity, a significant survival benefit was limited to lipophilic statin users and those who took statins of moderate intensity. CONCLUSIONS: This SEER-Medicare analysis demonstrates improvement in overall survival with lipophilic statin use after surgery in elderly patients with epithelial ovarian cancer. A clinical trial to evaluate the impact of statin treatment in ovarian cancer survival is warranted.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Vogel TJ, Goodman MT, Li AJ, et al. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer. Gynecol Oncol. 2017. PMID: 28596017. doi:10.1016/j.ygyno.2017.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。